Ivermectin for COVID-19 : promising but not yet conclusive

Simple item page
dc.contributor.authorVan Rensburg, Rolanden_ZA
dc.contributor.authorDecloedt, Eric H.en_ZA
dc.contributor.authorReuter, Helmuthen_ZA
dc.contributor.authorParker, Arifaen_ZA
dc.contributor.authorSchrueder, Neshaaden_ZA
dc.contributor.authorLahri, Sa'aden_ZA
dc.date.accessioned2021-07-13T12:57:22Z
dc.date.available2021-07-13T12:57:22Z
dc.date.issued2021-03
dc.descriptionCITATION: Van Rensburg, R. et al. 2021. Ivermectin for COVID-19 : promising but not yet conclusive. South African Medical Journal, 111(3):188, doi:10.7196/SAMJ.2021.v111i3.15522.
dc.descriptionThe original publication is available at http://www.samj.org.za
dc.description.abstractIvermectin has been proposed as a potential definitive and prophylactic treatment for COVID-19.[1] Ivermectin is an anthelmintic drug that is usually indicated for filarial and resistant scabies infections, but has been shown to have antiviral activity and anti-inflammatory activity in vitro.[2,3] Ivermectin has the potential to be a promising directed therapy in the drug armamentarium against COVID-19, as it has been shown to have in vitro activity against SARS-CoV-2.[4] Several randomised controlled trials (RCTs) and observational studies have reported on the effectiveness and safety outcomes of ivermectin in COVID-19.[1,5] These data are very promising, showing large treatment effects and acceptable adverse effect profiles for ivermectin against COVID-19, especially when combined in metaanalyses.en_ZA
dc.description.versionPublisher's version
dc.format.extent1 pageen_ZA
dc.identifier.citationVan Rensburg, R. et al. 2021. Ivermectin for COVID-19 : promising but not yet conclusive. South African Medical Journal, 111(3):188, doi:10.7196/SAMJ.2021.v111i3.15522.
dc.identifier.issn2078-5135 (online)
dc.identifier.issn0256-9574 (print)
dc.identifier.otherdoi:10.7196/SAMJ.2021.v111i3.15522
dc.identifier.urihttp://hdl.handle.net/10019.1/110718
dc.language.isoen
dc.publisherHealth & Medical Publishing Group
dc.rights.holderAuthors retain copyright
dc.subjectAnthelminthicsen_ZA
dc.subjectDrug developmenten_ZA
dc.subjectDrugs -- Effectivenessen_ZA
dc.subjectIvermectinen_ZA
dc.subjectAnthelmintics
dc.titleIvermectin for COVID-19 : promising but not yet conclusiveen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
vanrensburg_ivermectin_2021.pdf
Size:
64.26 KB
Format:
Adobe Portable Document Format
Description:
Download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Clinical Pharmacology)